Lenskart vs Titan EyeCare: margins and manufacturing tilt the eyewear battle

Post-listing at Rs 390, Lenskart posts Q2 FY26 revenue of Rs 2,146.6 crore (+24% YoY) with 19.8% EBITDA margin and 69.2% product margin, aided by in-house frame production. Titan EyeCare income edged up to Rs 215 crore but segment EBIT fell to Rs 12 crore from Rs 24 crore in India's ~$9.2bn market.

— FiledWed, 15 Jul, 2026, 12:50 IST·First seen Wed, 15 Jul, 2026, 12:49 IST·Source Financial Express · BrandWagon

What happened

Comparison of Lenskart and Titan EyeCare in India's ~$9.2bn eyewear market post-Lenskart listing. Lenskart shows stronger margins and in-house manufacturing

Key facts

  • Lenskart listed at Rs 390 on NSE, 3% below issue price of Rs 402
  • declined 2.23% in last month
  • Titan gained 0.99% last month, 10.85% last year
  • Indian eyewear market ~$9.2 billion / Rs 30,000 crore
  • Titan share under 12%
  • 9.3 million eye tests H1 FY26, 46% first-time users
  • 203 net new stores, 431 cities
  • next-day delivery in 58 cities
  • Lenskart Q2 product margin 69.2%
  • local frame production 35%-40% cost advantage, ~4 million frames H1
  • Lenskart Q2 FY26 revenue Rs 2,146.6 crore, up 24% YoY
  • EBITDA Rs 425.8 crore at 19.8% margin
  • H1 FY26 EBITDA margin 19.5% vs 17.3%
  • Titan EyeCare income Rs 215 crore vs Rs 199 crore
  • segment EBIT Rs 12 crore vs Rs 24 crore, margin ~5.3%-5.7%
  • 871 exclusive EyeCare stores as of Sep 2025

Why this matters

Titan EyeCare's eroding profitability against a vertically integrated Lenskart points to build-vs-buy pressure, making manufacturing capacity or brand acquisitions strategically urgent to defend segment economics.

What to watch

  • Lenskart Q3 FY26 EBITDA margin trajectory (holding above 19% vs compression)
  • Titan EyeCare EBIT recovery or further decline below Rs 12 crore
  • Lenskart same-store sales growth and new store additions
  • Frame/lens input cost and import-substitution economics
  • Lenskart post-lockup share price behavior vs Rs 390 listing
  • Lenskart reinvests post-listing capital into domestic manufacturing capacity and store network expansion
  • Titan reviews EyeCare pricing/product mix, likely tilting to premium frames and lens add-ons to restore EBIT
  • Analysts reset Lenskart valuation against Titan's segment multiple; watch for coverage initiations post-listing
  • Both intensify private-label and lens-technology (blue-light, progressive) push to protect product margins